An interventional study of Remote Monitoring and On site monitoring in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus, sponsored by University Of Perugia. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by University Of Perugia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Arthritis, Rheumatoid with a site in Italy — 20 open to participants now, 30 under way, 3 of them phase 3. Arthritis, Rheumatoid · Italy.
Among the 189 studies in Arthritis, Rheumatoid with a site in Italy, this one is the 96th largest by planned enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 with no phase, reaches primary completion later than 7 of the 29 other live ones, and was the 175th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →20 of the 189 studies in Arthritis, Rheumatoid with a site in Italy are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 8 more countries
Ages 18–65
Philogen S.p.A. · Sites in Italy
Ages 18–80
Merck Sharp & Dohme LLC · Sites in Italy, Australia, Belgium and 8 more countries
Ages 18–75
GlaxoSmithKline · Sites in Italy, Argentina, Brazil and 6 more countries
Ages 18–70
Hoffmann-La Roche · Sites in Italy, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 40 · Phase 3 69 · Phase 4 21
First in 2000; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 319 across the 146 interventional studies, 255 across the 43 observational. Of the 150 that completed or were terminated, 106 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
161 of 189 have an industry lead sponsor. The 10 most frequent:
University Of Perugia is the lead sponsor of 55 studies on the registry; 12 are open to participants now.
University Of Perugia has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Rheumatoid with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT07680101Universita di VeronaIntra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration. | 2027-06 |
| NCT02038140Zimmer BiometZimmer Trabecular Metal Total Ankle PMCF | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 189 studies in Arthritis, Rheumatoid with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of complications and allowing the best possible quality of life for patients.
The drugs used for treating these diseases are mostly immunosuppressants, which reduce the activity of the immune system, whose alteration is responsible for the disease. Although all available drugs are effective for treating these diseases, for reasons largely unknown, each drug is effective only in a percentage of patients. As a result, it is often necessary to try several different treatments before identifying an effective one for the individual patient.
The therapeutic effects are often slow, and it is therefore necessary to take a treatment for weeks or months before its effectiveness can be determined. The initial period is also when side effects most often appear. The aim of this study is to evaluate whether the addition of remote monitoring visits and other patient support services to traditional periodic medical visits in the first months after the introduction of a new treatment leads to an improvement in adherence, response, and quality of life for the patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any patient with one of the following conditions
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Remote Monitoring · Other: On site monitoring
Other: On site monitoring
Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription
Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
Treatment persistence
Percentage of patients taking the same medication prescribed at baseline
Time frame: 6 months
Treatment Persistence
Percentage of patients taking the same medication prescribed at baseline
Time frame: 3 months
Disease activity score on 28 joints with C-Reactive Protein (DAS28-CRP)
Only applies to rheumatoid arthritis patients
Time frame: 3 months
Disease activity score on 28 joints with C-Reactive Protein (DAS28-CRP)
Only applies to rheumatoid arthritis patients
Time frame: 6 months
Psoriatic Arthritis Disease Activity Score (PASDAS)
Only applies to psoriatic arthritis patients
Time frame: 3 months
Psoriatic Arthritis Disease Activity Score (PASDAS)
Only applies to psoriatic arthritis patients
Time frame: 6 months
Body Surface Area (BSA)
Percentage of skin surface with psoriatic lesions. Only applies to psoriatic arthritis patients
Time frame: 3 months
Body Surface Area (BSA)
Percentage of skin surface with psoriatic lesions. Only applies to psoriatic arthritis patients
Time frame: 6 months
Minimal Disease Activity (MDA)
Binary outcome. Only applies to psoriatic arthritis patients
Time frame: 3 months
Minimal Disease Activity (MDA)
Binary outcome. Only applies to psoriatic arthritis patients
Time frame: 6 months
Modified Rodnan's skin score
Only applies to systemic sclerosis patients
Time frame: 3 months
Modified Rodnan's skin score
Only applies to systemic sclerosis patients
Time frame: 6 months
Medical Research Council (MRC) dyspnoea scale
Only applies to systemic sclerosis patients with interstitial lung disease
Time frame: 3 months
Medical Research Council (MRC) dyspnoea scale
Only applies to systemic sclerosis patients with interstitial lung disease
Time frame: 6 months
EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
Only applies to Sjogren's disease patients
Time frame: 3 months
EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
Only applies to Sjogren's disease patients
Time frame: 6 months
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)
Only applies to Sjogren's disease patients
Time frame: 3 months
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)
Only applies to Sjogren's disease patients
Time frame: 6 months
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K
Only applies to systemic lupus erythematosus patients
Time frame: 3 months
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K
Only applies to systemic lupus erythematosus patients
Time frame: 6 months
Ankylosing Spondylitis Disease Activity Score (ASDAS)
Only applies to ankylosing spondylitis and axial spondyloarthritis patients
Time frame: 3 months
Ankylosing Spondylitis Disease Activity Score (ASDAS)
Only applies to ankylosing spondylitis and axial spondyloarthritis patients
Time frame: 6 months
Health Assessment Questionnaire Disability Index (HAQ-DI)
Range 0 (best condition) - 3 (worst condition)
Time frame: 3 months
Health Assessment Questionnaire Disability Index (HAQ-DI)
Range 0 (best condition) - 3 (worst condition)
Time frame: 6 months
Anxiety and Depression
Hospital Anxiety and Depression Scale - Anxiety and Depression range 0 - 21 each (higher values mean higher degrees of depression or anxiety)
Time frame: 3 months
Anxiety and Depression
Hospital Anxiety and Depression Scale - Anxiety and Depression range 0 - 21 each (higher values mean higher degrees of depression or anxiety)
Time frame: 6 months
EQ-5D-5L score
The score measures quality of life and includes 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is scored from 1 (perfect health) to 5 (complete inability).
Time frame: 3 months
EQ-5D-5L score
The score measures quality of life and includes 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is scored from 1 (perfect health) to 5 (complete inability).
Time frame: 6 months
Number of phone calls to Rheumatology Outpatient Clinic
Time frame: 6 months
Number of additional, unscheduled rheumatology consultations
Time frame: 6 months
Number of consultations to GP due to prescribed treatment-related issues
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Mar 2026, 20 months after the start.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 20 months is below that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Of Perugia